Blogs
Welcome to Unibest's Blogs section! Here, you will find valuable insights and in-depth reports covering various topics related to drugs and diseases. Our blogs aim to provide an enhanced understanding of the clinical significance and breakthroughs your clients can make. Stay updated with the latest trends, technological advancements, and industry analyses as we dive deep into the world of pharmaceuticals, giving you the knowledge and resources you need to stay ahead of the competition.

Valsartan

These are related to the Valsartan news, in which you can learn about the latest trends in Valsartan and related information industry, to help you better understand and expand Valsartan market.
  • Drug Patent & Exclusivity Expiration Report - Week of July 14 2025

    2025-07-14

    This week, there are 6 drugs in the patent and exclusivity list. They are: - NOVARTIS PHARMACEUTICALS CORP's ENTRESTO, containing active ingredient SACUBITRIL; VALSARTAN - BIOCODEX SA's DIACOMIT, containing active ingredient STIRIPENTOL - PF PRISM CV's XALKORI, containing active ingredient CRIZOTINIB - INCYTE CORP's OPZELURA, containing active ingredient RUXOLITINIB PHOSPHATE - SERVIER PHARMACEUTICALS LLC's TIBSOVO, containing active ingredient IVOSIDENIB - GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LTD ENGLAND's KRINTAFEL, containing active ingredient TAFENOQUINE SUCCINATE Read More
  • Drug Patent & Exclusivity Expiration Report - Week of Jan 13 2025

    2025-01-13

    This week, there are 6 drugs in the patent and exclusivity list. They are: - BAUSCH AND LOMB INC's BEPREVE, containing active ingredient BEPOTASTINE BESILATE - ITALFARMACO SPA's DUVYZAT, containing active ingredient GIVINOSTAT HYDROCHLORIDE - NOVARTIS PHARMACEUTICALS CORP's ENTRESTO & ENTRESTO SPRINKLE, containing active ingredient SACUBITRIL; VALSARTAN - GLENMARK SPECIALTY SA's RYALTRIS, containing active ingredient MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE - ABBVIE INC's RINVOQ, containing active ingredient UPADACITINIB Read More